Generic placeholder image

Current Drug Targets - Immune, Endocrine & Metabolic Disorders


ISSN (Print): 1568-0088
ISSN (Online): 1875-5917

Management of Liver Disease in Thalassemia: Main Drug Targets for a Correct Therapy

Author(s): G. C. D. Vecchio, A. Nigro, P. Giordano and D. De Mattia

Volume 5, Issue 4, 2005

Page: [373 - 378] Pages: 6

DOI: 10.2174/1568005310505040373

Price: $65


Liver disease is the second cause of mortality in thalassemia major. We present a review on the hepatic damage in thalassemic patients aimed at a knowledge of current preventive, diagnostic and therapeutic approaches, useful to guide in clinical judgment and treatment decisions. Transfusion related iron overload and hepatitis are the causes of liver damage in thalassemic patients. We examined means of primary prevention, anti-hepatitis vaccinations, blood donors screening; diagnostic tests for secondary prevention (computed tomography, magnetic resonance imaging, super conducting quantum interference device and biopsy) were also discussed about. A survey of treatment methods and strategies ( chelation therapy, antiviral treatments and liver and bone marrow transplantation) follows.

Keywords: Thalassemia, liver disease, iron overload, HCV infection

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy